The proposed legislation is expected to have a significant impact on state laws governing pharmacy operations and healthcare costs. By formalizing the requirements for PBMs regarding formulary revisions and rebates, the bill aims to enhance the protection of consumers and pharmacies, ensuring that they are not subject to arbitrary changes that could affect access to necessary medications. The inclusion of a 60-day continuity-of-care period is designed to mitigate disruptions for patients, particularly those on long-term prescriptions. These changes could reduce the financial burden on consumers by limiting unnecessary out-of-pocket expenses associated with sudden formulary changes.
Summary
SB381 aims to regulate the actions of pharmacy benefit managers (PBMs) by implementing restrictions on their ability to change drug formularies and manage prescription drug costs. The bill establishes provisions that require PBMs to maintain a continuity-of-care period when a drug is removed from the formulary, ensuring that insured individuals can continue to receive their medications without unexpected changes in cost or availability during the policy year. Furthermore, the bill prohibits PBMs from obtaining rebates from manufacturers for name brand drugs in exchange for omitting other drugs from the formulary, thus promoting greater transparency and efficiency in drug pricing.
Sentiment
The sentiment surrounding SB381 appears to be supportive among healthcare advocates and pharmacy representatives, who view the bill as a necessary step in increasing fairness and accountability within the PBM system. Supporters argue that the bill aligns with consumer interests by safeguarding access to medication and promoting affordability. However, some industry stakeholders express concerns regarding the potential operational burdens it may impose on PBMs and the pharmaceutical industry, highlighting the complexities of managing formularies in compliance with the new regulations.
Contention
Key contention points in the discussions around SB381 center on the balance of power between PBMs and pharmacies, as well as the need for accountability in pharmaceutical rebates. Critics fear the bill might limit the flexibility of PBMs in managing drug costs and negotiations with manufacturers. Additionally, some legislators question whether the proposed measures will sufficiently enhance affordability without inadvertently leading to increased premiums for consumers. A significant focus remains on finding solutions that satisfy both the need for cost control and access to affordable medications.
Urges the attorney general and the Louisiana Department of Insurance to investigate pharmacy benefit managers (PBMs) for potential violations of law and to urge and request the legislature to pass legislation prohibiting PBMs from owning or having a financial interest in pharmacies in this state